TABLE 3.
Fab 3674 neutralizes the diverse primary isolatesa
| HIV-1 Env subtype and strain | IC50 (μg/ml)b for:
|
|
|---|---|---|
| bF-3674 | mF-3674 | |
| Subtype B | ||
| B.AC10.0.29 | 28 ± 8 | 88 ± 15 |
| B.CAAN5342.A2 | 28 ± 6 | 94 ± 11 |
| B.SC422661.8 | 30 ± 7 | 185 ± 36 |
| B.QH0692.42 | 71 ± 12 | 209 ± 32 |
| B.WITO4160.33 | 104 ± 35 | 76 ± 29 |
| B.REJO4541.67 | 128 ± 66 | 106 ± 16 |
| B.RHPA4259.7 | 150 ± 54 | 296 ± 72 |
| B.THRO4156.18 | 231 ± 82 | 373 ± 135 |
| B.TRJO4551.58 | 82 ± 28 | NA |
| B.TRO.11 | 86 ± 27 | NA |
| B.PVO.4 | NA | NA |
| B.6535.3 | NA | NA |
| Subtype A | ||
| A.DJ263.8 | 158 ± 29 | 210 ± 68 |
| A.RW020 | 74 ± 21 | 145 ± 46 |
| Subtype C | ||
| C.ZM233M.PB6 | 6 ± 2 | 10 ± 3 |
| C.DU172.17 | 24 ± 3 | 157 ± 44 |
a
The viruses were pseudotyped with Envs from the standard reference panel of subtype B (28) and C (44) HIV-1 clones and with Env from subtype A HIV-1 strains derived from primary isolates.
b
NA, no activity: in the range of concentrations of Fabs tested, viral neutralization was too weak to reliably determine an IC50 value.